Featured Video Play Icon
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.
  • SavvyWire is the world’s first and only sensor-guided transcatheter aortic valve replacement (TAVR) solution
  • The TAVR was performed by Dr. Philippe Genereux, Director of the Structural Heart Program at Morristown Medical Center in New Jersey, and his team
  • The company will release SavvyWire to a limited number of U.S. hospitals through 2022, followed by a full launch in early 2023
  • OpSens offers fibre optic sensing technology for the medical, energy and industrial sectors
  • OpSens (OPS) closed down by 3.64 per cent, trading at $2.65 per share

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

The TAVR was performed by Dr. Philippe Genereux, Director of the Structural Heart Program at Morristown Medical Center in New Jersey, and his team.

SavvyWire is the world’s first and only sensor-guided TAVR solution. It provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement, and reliable left ventricular pacing without the need for adjunct devices or venous access.

The company will release SavvyWire to a limited number of U.S. hospitals through 2022, followed by a full launch in early 2023.

“I am extremely pleased with the performance of the SavvyWire,” said Dr. Genereux. “We successfully treated 10 consecutive patients with a variety of anatomies and levels of complexity, including bicuspid valve, severe vessel tortuosity, horizontal aorta, failed prior surgical valve (valve-in-valve) using both balloon-expandable and self-expandable valves, and balloon valvuloplasty.”

“There is no doubt the SavvyWire allowed us to optimize our efficiency and workflow while enhancing accuracy and patient safety,” he added.

“Dr. Genereux’s prior work has been instrumental to the advancement and expansion of the TAVR field, and we are thrilled to be partnering with him and his team to streamline procedures and improve patient outcomes,” said Louis Laflamme, President and CEO of OpSens.

OpSens offers fibre optic sensing technology for the medical, energy and industrial sectors.

OpSens (OPS) closed down by 3.64 per cent, trading at $2.65 per share.


More From The Market Herald

" Galaxy Digital (TSX:GLXY) to launch inaugural NFT collection

Galaxy Digital (GLXY) will launch its first NFT project in collaboration with TIMEPieces.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.

" Railtown (CSE:RAIL) partners with Quisitive to empower software engineers

Railtown AI Technologies (RAIL) has signed a Service Provider License Agreement with Quisitive Technology Solutions.
Featured Video Play Icon

" Rapid Dose Therapeutics (CSE:DOSE) to supply leading gas and convenience store retailer

Rapid Dose (DOSE) has signed a supplier agreement with a leading gas and convenience store retailer.